Clinical Trial Update: Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating dasatinib in patients with core-binding factor acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: University Hospital, Angers | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: COMPLETED